Tuesday, August 4, 2026

Samsung Bioepis Signs Teva Deal to Commercialize Opuviz in Canada, Expanding North American Biosimilar Business

Samsung Bioepis partners with Teva to launch ophthalmology biosimilar Opuviz in Canada, enhancing access to treatments for patients.

SEC Prepares New Framework to Allow Blockchain-Based Trading of Tokenized Stocks

The SEC plans to unveil rules allowing blockchain-based stock token trading, enhancing flexibility in securities markets.

ABL Bio to Invest Additional $25 Million in Neok Bio to Accelerate ADC Clinical Trials

ABL Bio invests $25M in Neok Bio for bispecific antibody-drug conjugate trials, aiming for FDA-approved treatments by 2027.

Tag: CDK7 inhibitor

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Qurient Mocaciclib’s CDK7 Inhibitor is Revolutionizing High-Risk Pediatric Brain Cancer Therapy

Qurient's Mocaciclib shows promising results for pediatric brain tumors, enhancing survival and overcoming treatment barriers.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.